US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
GB9325445D0
(en)
*
|
1993-12-13 |
1994-02-16 |
Cortecs Ltd |
Pharmaceutical formulations
|
US5567592A
(en)
*
|
1994-02-02 |
1996-10-22 |
Regents Of The University Of California |
Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
|
GB9405304D0
(en)
*
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
DE4443175A1
(de)
*
|
1994-12-05 |
1996-06-13 |
Jenapharm Gmbh |
Neue pulsatile Arzneiform
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
WO1996024332A1
(en)
*
|
1995-02-06 |
1996-08-15 |
Nanosystems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
US5665386A
(en)
*
|
1995-06-07 |
1997-09-09 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
JPH11507356A
(ja)
*
|
1995-06-07 |
1999-06-29 |
アブマックス,インコーポレイティド |
経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
|
US5716928A
(en)
*
|
1995-06-07 |
1998-02-10 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US6024980A
(en)
*
|
1996-06-28 |
2000-02-15 |
Mcneil-Ppc, Inc. |
Multiphase soft gelatin dosage form
|
ES2322405T3
(es)
*
|
1996-07-08 |
2009-06-19 |
Penwest Pharmaceuticals Co. |
Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
|
US6458373B1
(en)
*
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US20030008919A1
(en)
*
|
1999-06-03 |
2003-01-09 |
Jean-Baptiste Roullet |
Use of retinoids to treat high blood pressure and other cardiovascular disease
|
JP2002500190A
(ja)
|
1998-01-08 |
2002-01-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
海洋海綿から誘導されるキネシンモーターモジュレーター
|
US7030155B2
(en)
*
|
1998-06-05 |
2006-04-18 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6200968B1
(en)
*
|
1998-08-06 |
2001-03-13 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
FR2782006B1
(fr)
*
|
1998-08-07 |
2002-04-19 |
Gattefosse Ets Sa |
Composition a liberation prolongee apte a former une micro-emulsion
|
AU775523B2
(en)
|
1998-12-11 |
2004-08-05 |
Pharmasolutions, Inc. |
Self-emulsifying compositions for drugs poorly soluble in water
|
US6057289A
(en)
*
|
1999-04-30 |
2000-05-02 |
Pharmasolutions, Inc. |
Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
|
EP1280533A2
(en)
*
|
2000-05-11 |
2003-02-05 |
Pharmacia Corporation |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
EP1492511B3
(fr)
*
|
2002-04-09 |
2012-05-02 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US20040077621A1
(en)
*
|
2002-08-08 |
2004-04-22 |
Academia Sinica |
Antioxidants
|
CA2515544A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Kemia Inc. |
Compounds for the treatment of viral infection
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
AU2005204391A1
(en)
*
|
2004-01-14 |
2005-07-28 |
Lavipharm Laboratories, Inc. |
Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
|
AU2005212005A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
JP4980211B2
(ja)
|
2004-05-12 |
2012-07-18 |
ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
細胞単離方法
|
WO2006095347A2
(en)
|
2005-03-10 |
2006-09-14 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
|
US8648045B2
(en)
|
2005-03-10 |
2014-02-11 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VDAC1 compositions and methods of use thereof for regulating apoptosis
|
EA012440B1
(ru)
|
2005-04-29 |
2009-10-30 |
Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье |
Пептид, композиция на его основе для лечения патологий, связанных c воспалительными процессами
|
EP2407484B1
(en)
|
2005-06-24 |
2016-06-22 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
CA2637350A1
(en)
|
2006-01-20 |
2007-07-26 |
Child Health Research Institute Inc |
Method of treatment, prophylaxis and diagnosis of pathologies of the bone
|
US8440788B2
(en)
*
|
2006-04-06 |
2013-05-14 |
Ben-Gurion University Of The Negev Research And Development Authority Ltd. |
N-terminal VDAC variants and uses thereof
|
WO2007123153A1
(ja)
*
|
2006-04-19 |
2007-11-01 |
Ono Pharmaceutical Co., Ltd. |
経口投与用カプセル
|
MY153288A
(en)
*
|
2006-06-28 |
2015-01-29 |
Hovid Berhad |
An effective pharmaceutical carrier for poorly bioavailable drugs
|
KR101390695B1
(ko)
*
|
2006-08-01 |
2014-04-30 |
오츠카 세이야쿠 가부시키가이샤 |
약리 활성 물질의 흡수성이 개선된 의약 조성물
|
AU2007309408A1
(en)
*
|
2006-10-27 |
2008-05-02 |
Janssen Pharmaceutica N.V. |
Dry granulated pharmaceutical compositions and methods for producing same
|
US8252897B2
(en)
*
|
2007-06-21 |
2012-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
CN101835490A
(zh)
|
2007-08-02 |
2010-09-15 |
阿雷斯托生物科学股份有限公司 |
Lox和loxl2抑制剂及其应用
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
DK2195331T3
(da)
*
|
2007-08-28 |
2014-02-03 |
Uab Research Foundation |
Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
|
PT2205245E
(pt)
*
|
2007-10-03 |
2015-10-13 |
Wista Lab Ltd |
Utilização terapêutica de diaminofenotiazinas
|
EP2268297A4
(en)
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
EP2276445B1
(en)
*
|
2008-05-12 |
2012-07-04 |
Capsugel Belgium NV |
Improved capsule with air-vents
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
CN102711809B
(zh)
|
2009-08-17 |
2015-09-30 |
特雷康制药公司 |
使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
|
ES2363965B1
(es)
*
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US9249189B2
(en)
|
2010-01-18 |
2016-02-02 |
Albany Medical College |
Alpha-fetoprotein “ring and tail” peptides
|
ES2739505T3
(es)
|
2010-08-27 |
2020-01-31 |
Gilead Biologics Inc |
Anticuerpos contra la metaloproteinasa 9 de la matriz
|
WO2012051567A2
(en)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Obesity-related genes and their proteins and uses thereof
|
CA2834657A1
(en)
|
2011-04-29 |
2012-11-01 |
Kinemed, Inc. |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
JP6368645B2
(ja)
|
2011-09-29 |
2018-08-01 |
ピーエルエックス オプコ インコーポレーテッド |
胃腸管に沿った医薬の標的化放出のためのpH依存性担体、それによる組成物、ならびにこれらの製造および使用
|
WO2013130078A1
(en)
|
2012-02-29 |
2013-09-06 |
Gilead Biologics, Inc. |
Antibodies to matrix metalloproteinase 9
|
EP3255063A3
(en)
|
2012-02-29 |
2018-02-07 |
Gilead Biologics, Inc. |
Antibodies to matrix metalloproteinase 9
|
WO2013128453A1
(en)
|
2012-03-01 |
2013-09-06 |
Yeda Research And Development Co. Ltd. |
Regeneration of islet beta cells by hsp60 derived peptides
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
TW201406707A
(zh)
|
2012-05-04 |
2014-02-16 |
Acucela Inc |
用以治療糖尿病性視網膜病變及其他眼部疾病之方法
|
US10441636B2
(en)
|
2012-07-20 |
2019-10-15 |
La Trobe University |
Method of diagnosis and treatment
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
JP6570511B2
(ja)
|
2013-03-14 |
2019-09-04 |
ユーエイビー リサーチ ファンデーション |
アポリポタンパク質模倣体及びその使用
|
WO2014144708A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
DK2968503T3
(en)
|
2013-03-15 |
2018-12-03 |
Intrinsic Lifesciences Llc |
ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
|
US9758559B2
(en)
|
2013-07-25 |
2017-09-12 |
B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University |
Short peptides derived from VDAC1, compositions and methods of use thereof
|
CN105873944A
(zh)
|
2013-12-20 |
2016-08-17 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
促血管发生的肽和肽缀合物
|
TW201544511A
(zh)
|
2014-02-27 |
2015-12-01 |
Gilead Sciences Inc |
針對基質金屬蛋白酶9之抗體及其使用方法
|
CA2951535A1
(en)
|
2014-06-11 |
2015-12-17 |
Gilead Sciences, Inc. |
Methods for treating cardiovascular diseases
|
US10793614B2
(en)
|
2014-07-17 |
2020-10-06 |
Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. |
Antagonists of fish reproduction
|
EP3169700A1
(en)
|
2014-07-17 |
2017-05-24 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antagonists of neurokinin b in fish reproduction
|
JP7081923B2
(ja)
|
2014-07-31 |
2022-06-07 |
ユーエイビー リサーチ ファンデーション |
アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
|
US20160074473A1
(en)
|
2014-07-31 |
2016-03-17 |
Kinemed, Inc. |
Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
|
NZ730186A
(en)
|
2014-09-22 |
2020-04-24 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
CN108884135B
(zh)
|
2015-10-27 |
2024-03-26 |
昆士兰大学 |
治疗方法以及可用于其中的药剂
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
US20170306050A1
(en)
|
2016-04-08 |
2017-10-26 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
WO2018071814A1
(en)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
AU2018212937A1
(en)
|
2017-01-30 |
2019-08-15 |
Hudson Institute of Medical Research |
A method of treatment
|
WO2018213803A1
(en)
|
2017-05-19 |
2018-11-22 |
Neon Therapeutics, Inc. |
Immunogenic neoantigen identification
|
KR102344616B1
(ko)
|
2017-05-30 |
2021-12-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
항-더블코르틴-유사 키나제 1 항체 및 사용 방법
|
CA3081840A1
(en)
|
2017-11-08 |
2019-05-16 |
Neon Therapeutics, Inc. |
T cell manufacturing compositions and methods
|
GB2603044A
(en)
|
2019-06-11 |
2022-07-27 |
Myeloid Therapeutics Inc |
Macrophage specific engager compositions and methods of use thereof
|
KR20220062488A
(ko)
|
2019-06-12 |
2022-05-17 |
바이오엔테크 유에스 인크. |
신생항원 조성물 및 이의 용도
|
AU2021244695A1
(en)
|
2020-03-26 |
2022-11-10 |
Plx Opco Inc. |
Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
|
CA3189285A1
(en)
|
2020-08-13 |
2022-02-17 |
Vikram JUNEJA |
T cell manufacturing compositions and methods
|
WO2022098905A2
(en)
|
2020-11-04 |
2022-05-12 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|